TNFRSF17 and Miyoshi myopathy: However, several clinical trials have also observed non-responders and relapses despite the persistent expression of BCMA on MM cells (4, 8, 9), an indication that failure with CAR T-cell therapy may also potentially occur as a result of insufficient expansion, lack of persistence, or loss of efficacy of CAR T-cells.